Center for Veterinary Biologics (CVB) has granted the company a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus. This vaccine is approved for use in chickens. The ...

The U.S. Department of Agriculture has given a conditional approval to Zoetis to use its bird flu vaccine in poultry, the ...

Zoetis slightly topped analyst estimates for profitability and met those for revenue in its fourth quarter. But as investors ...

Zoetis said the U.S. Department of Agriculture's Center for Veterinary Biologics issued the company a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus. The vaccine is ...

Zoetis (ZTS) announced that the U.S. Department of Agriculture, Center for Veterinary Biologics, has issued the company a conditional license ...

Zoetis today announced that the U.S. Department of Agriculture (USDA), Center for Veterinary Biologics (CVB) has issued the ...

BofA lowered the firm’s price target on Zoetis (ZTS) to $200 from $205 and keeps a Buy rating on the shares. Zoetis reported “solid” Q4 results ...

Zoetis CEO Kristin Peck joins 'Closing Bell Overtime' to talk its Avian Flu vaccine, the impact of tariffs, and more.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance. Click here to find ...

Zoetis is the undisputed leader in the global animal health industry, and we believe it possesses the widest moat of all the competitors. Zoetis has set itself apart based on its impressive innovation ...

What Happened? Shares of animal health company Zoetis (NYSE:ZTS) fell 10.6% in the morning session after the company reported ...